Quanome Technologies, Inc. (Nasdaq: QNME) reported results for its fiscal first quarter ended September 30, 2026, highlighting a pivot in business focus toward quantum and AI opportunities. The company announced that its established pharmaceutical distribution business, Hupan Pharmaceutical (Hubei) Co., Ltd., continued to provide the primary revenue base as its new AI subsidiary prepared to launch services.
During the quarter, Quanome entered into an approximately $18.8 million agreement to purchase 32 NVIDIA-powered GPU servers for the first U.S. AI inference hub of XDT Infrastructure I, LLC, its indirect wholly owned subsidiary. The company reported quarterly revenue of $2.05 million, representing a 53% year-over-year increase. Gross profit for the period was $1.10 million, which management noted doubled primarily due to higher supplier rebates. XDT remained pre-revenue at the quarter-end.
Following the quarter, Quanome announced significant developments regarding its AI computing business. On October 29, 2026, XDT secured its first enterprise customer agreement and received a $13.5 million prepayment toward future services. The initial order has a total commitment value exceeding $100 million over a 60-month term that begins upon service commencement, subject to contractual conditions. Additionally, Quanome agreed to purchase a further 32 GPU servers on September 29, 2026, bringing the total under purchase agreements to 64 units.
Management anticipates that initial service revenue from XDT will commence in the second or third quarter of fiscal 2027, subject to successful deployment and the satisfaction of service-start conditions. Separately, on November 9, 2026, Quanome announced an all-stock agreement to acquire approximately 5% of QAI Labs, an independent life sciences technology company developing the NOVA-3 platform.